: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription

Articles published in Prostate
Retrieve available abstracts of 253 articles:
HTML format

Single Articles

August 2025

CASTILLO LC, Belenchon IR, Sanz IP, Marenco RS, et al
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.
Prostate. 2025;85:1016-1023.
PubMed Abstract available

BERTINI A, Stephens A, Finocchiaro A, Silvia V, et al
Association of Area of Deprivation Index With Active Surveillance (AS) Utilization and Adherence to as Guidelines: Results From a Contemporary North American Cohort.
Prostate. 2025;85:1024-1035.
PubMed Abstract available

July 2025

SHARIFI MN, Heninger E, Bootsma ML, Recchia EE, et al
Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer.
Prostate. 2025 Jul 2. doi: 10.1002/pros.70000.
PubMed Abstract available

June 2025

GRUBER I, Koelbl O, Meier MM
Late Bowel Symptoms in Long-Term Survivors of Prostate Cancer Following Radiotherapy.
Prostate. 2025 Jun 24. doi: 10.1002/pros.70004.
PubMed Abstract available

GRUTMAN AJ, Jing Y, Ng DK, Landis PK, et al
History of Vasectomy Is not Associated With Prostate Cancer Progression in Men on Active Surveillance.
Prostate. 2025 Jun 23. doi: 10.1002/pros.70001.
PubMed Abstract available

TAKAHASHI T
Evidence and Rationale for Prostate Cancer Screening.
Prostate. 2025 Jun 22. doi: 10.1002/pros.70002.
PubMed

LEMSTER AL, Grunhagen S, Schmalfeld S, Lenz F, et al
Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer.
Prostate. 2025 Jun 12. doi: 10.1002/pros.24925.
PubMed Abstract available

YANG YJ, Zeng C, Schaffer KR, Tran TC, et al
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
Prostate. 2025 Jun 11. doi: 10.1002/pros.24913.
PubMed Abstract available

FUKUSHIMA T, Goto K, Nakano Y, Tasaka S, et al
Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.
Prostate. 2025 Jun 10. doi: 10.1002/pros.24926.
PubMed Abstract available

HORVATH A, Blasszauer C, Komka I, Reibl D, et al
Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.
Prostate. 2025 Jun 8. doi: 10.1002/pros.24923.
PubMed Abstract available

XUE C, Ko HK, Shi K, Pittsenbarger J, et al
Understanding Enzalutamide-Resistance Based on a Functional Single-Cell Approach.
Prostate. 2025;85:888-899.
PubMed Abstract available

MIURA Y, Yoneyama T, Yamamoto H, Suzuki H, et al
Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population.
Prostate. 2025;85:869-887.
PubMed Abstract available

May 2025

ODERDA M, Orlando G, Calleris G, Capella G, et al
Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance.
Prostate. 2025 May 29. doi: 10.1002/pros.24921.
PubMed Abstract available

YANG P, Yang B
A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.
Prostate. 2025 May 26. doi: 10.1002/pros.24920.
PubMed Abstract available

ONAL C, Elmali A, Demirhan B, Guler OC, et al
SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.
Prostate. 2025 May 26. doi: 10.1002/pros.24919.
PubMed

FENG F, Xu Z
Bimodal Imaging: Detection Rate of Clinically Significant Prostate Cancer Is Higher in MRI Lesions Visible to Transrectal Ultrasound.
Prostate. 2025 May 23. doi: 10.1002/pros.24839.
PubMed

XU J, Lu J, Gielzak M, Lilly Zheng S, et al
Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.
Prostate. 2025 May 22. doi: 10.1002/pros.24918.
PubMed Abstract available

MIURA H, Hamaya T, Yoneyama T, Shimoyama T, et al
The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.
Prostate. 2025 May 22. doi: 10.1002/pros.24917.
PubMed Abstract available

QU LG, Vaselkiv JB, Perera M, Mucci L, et al
Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation.
Prostate. 2025 May 20. doi: 10.1002/pros.24915.
PubMed Abstract available

AGUILERA M, Klinkebiel DL, Williams V, Rovatti J, et al
Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA Hydroxymethylation in a Mouse Model of Prostate Cancer.
Prostate. 2025 May 11. doi: 10.1002/pros.24912.
PubMed Abstract available

MANDL A, Zahurak ML, Metri NA, Shore ND, et al
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.
Prostate. 2025 May 5. doi: 10.1002/pros.24903.
PubMed Abstract available

SAPERSTEIN L, Rowe SP, Gorin MA, Pienta KJ, et al
Impact of Concomitant Hormone Therapy on the Diagnostic Performance of (18)F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.
Prostate. 2025 May 4. doi: 10.1002/pros.24909.
PubMed Abstract available

RAHBAR K, Kidd M, Prasad V, David Rosin R, et al
Clinical Sensitivity and Specificity of the PROSTest in an American Cohort.
Prostate. 2025;85:558-566.
PubMed Abstract available

ARRIAGA-IZABAL D, Morales-Lazcano F, Canizalez-Roman A
Development and Validation of a Predictive Model of Prostate Screening Compliance: A Nationwide Population-Based Study.
Prostate. 2025;85:513-523.
PubMed Abstract available

LIN YH, Lin KJ, Shao IH
Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer.
Prostate. 2025;85:719-720.
PubMed

DIEUDONNE ZOJ, Gebreselassie KH, Mohammed TO, Khalid A, et al
Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?
Prostate. 2025;85:638-645.
PubMed Abstract available

ASIRI IM, Chen RC, Master V, Mi L, et al
Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors.
Prostate. 2025 May 1. doi: 10.1002/pros.24902.
PubMed Abstract available

April 2025

GOUVEIA A, Mesci A, Isfahanian N, Dayes I, et al
Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
Prostate. 2025 Apr 27. doi: 10.1002/pros.24905.
PubMed Abstract available

BACLE C, Mazancourt ES, Abid N, Ruffion A, et al
Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms.
Prostate. 2025 Apr 24. doi: 10.1002/pros.24906.
PubMed Abstract available

SRUTHI KK, Ummanni R
Valosin-Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy.
Prostate. 2025 Apr 23. doi: 10.1002/pros.24900.
PubMed Abstract available

DEE EC, Iyengar R, Narayan A, Feliciano EJG, et al
National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis of Global Data.
Prostate. 2025 Apr 15. doi: 10.1002/pros.24901.
PubMed Abstract available

SHIMOMURA T, Urabe F, Muramoto K, Yanagisawa T, et al
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.
Prostate. 2025 Apr 8. doi: 10.1002/pros.24898.
PubMed Abstract available

SHIMOMURA T, Otsuka N, Urabe F, Muramoto K, et al
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?
Prostate. 2025 Apr 6. doi: 10.1002/pros.24885.
PubMed Abstract available

OKAMURA T, Izumi K, Kurokawa S, Shima T, et al
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.
Prostate. 2025 Apr 3. doi: 10.1002/pros.24897.
PubMed Abstract available

PAE S, Sakamoto S, Zhao X, Tamura T, et al
LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy.
Prostate. 2025 Apr 2. doi: 10.1002/pros.24899.
PubMed Abstract available

ZHANG X, Sang W, Hong X, Qu H, et al
Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.
Prostate. 2025 Apr 2. doi: 10.1002/pros.24892.
PubMed Abstract available

BARABAN EG, Vlachou E, Patel S, Kates M, et al
Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
Prostate. 2025;85:443-447.
PubMed Abstract available

GAMAL A, Moschovas MC, Jaber AR, Saikali S, et al
Functional and Oncological Outcomes of Very Large Prostate Sizes Post Robotic Radical Prostatectomy: A Propensity Score-Matched Analysis.
Prostate. 2025;85:456-462.
PubMed Abstract available

TANG L, Wu M, Chen K, Gao F, et al
Automatic MRI-TRUS Fusion Technique for Transperineal Biopsy Guidance: From Preoperative Planning to Intraoperative Navigation.
Prostate. 2025;85:424-432.
PubMed Abstract available

SRIDHAR S, Abouelfetouh Z, Codreanu I, Gupta N, et al
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or
Prostate. 2025;85:413-423.
PubMed Abstract available

March 2025

MANTENA RV, Bhadouriya R, Jain U, Patel TA, et al
Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients.
Prostate. 2025 Mar 31. doi: 10.1002/pros.24887.
PubMed Abstract available

VASSALLO R, Mannas MP, Salcudean SE, Black PC, et al
Developments in Ultrasound-Based Imaging for Prostate Cancer Detection.
Prostate. 2025 Mar 28. doi: 10.1002/pros.24893.
PubMed Abstract available

LOSEE M, Kavanaugh M, Liu M, Borges N, et al
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.
Prostate. 2025 Mar 18. doi: 10.1002/pros.24880.
PubMed Abstract available

NG K, Priyadarshini G, Sarker SJ, Robinson A, et al
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate-Resistant Prostate Cancer (TRICREST).
Prostate. 2025 Mar 18:e24877. doi: 10.1002/pros.24877.
PubMed Abstract available

SUZUKI K, Hirata J, Okamura Y, Bando Y, et al
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of >/= 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis.
Prostate. 2025 Mar 16. doi: 10.1002/pros.24889.
PubMed Abstract available

MONDIA MWL, Batchala PP, Dreicer R, Devitt ME, et al
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.
Prostate. 2025 Mar 13. doi: 10.1002/pros.24890.
PubMed Abstract available

ONAL C, Guler OC, Erbay G, Demirhan B, et al
Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer.
Prostate. 2025 Mar 11. doi: 10.1002/pros.24888.
PubMed Abstract available

VIGANO S, Finati M, Stephens A, Bertini A, et al
Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North-American Cohort.
Prostate. 2025 Mar 11:e24882. doi: 10.1002/pros.24882.
PubMed Abstract available

CHEN G, Li Y, Geng S, Lv L, et al
Evaluating the Heterogeneity of Advanced Prostate Cancer by (18)F-DCFPyL and (18)F-FDG PET/CT in a Prospective Cohort.
Prostate. 2025 Mar 5. doi: 10.1002/pros.24881.
PubMed Abstract available

SHI Y, Wei X, Zhao F, Chen J, et al
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate.
Prostate. 2025 Mar 4:e24869. doi: 10.1002/pros.24869.
PubMed Abstract available

ROBINSON E, Kinsella N, Ap Dafydd D, Shur J, et al
Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.
Prostate. 2025 Mar 3. doi: 10.1002/pros.24886.
PubMed Abstract available

ORSINI A, Ferretti S, Porreca A, Castellan P, et al
PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers.
Prostate. 2025;85:337-343.
PubMed Abstract available

AYRANCI A, Caglar U, Yazili HB, Erdal FS, et al
PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI-RADS 3 Lesions.
Prostate. 2025;85:385-390.
PubMed Abstract available

ODERDA M, Marquis A, Bertero L, Calleris G, et al
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.
Prostate. 2025;85:374-384.
PubMed Abstract available

February 2025

CHEN H, Pang B, Liu Z, Li B, et al
The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.
Prostate. 2025 Feb 27. doi: 10.1002/pros.24879.
PubMed Abstract available

ESEN B, Seymen H, Armutlu A, Koseoglu E, et al
Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.
Prostate. 2025 Feb 27:e24884. doi: 10.1002/pros.24884.
PubMed Abstract available

ESENGUR OT, Stevenson E, Stecko H, Lay NS, et al
Assessing the Impact of Transition and Peripheral Zone PSA Densities Over Whole-Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI.
Prostate. 2025 Feb 25:e24863. doi: 10.1002/pros.24863.
PubMed Abstract available

HUNT TC, Cheng Z, Li A, Pamatmat AJ, et al
The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer.
Prostate. 2025 Feb 24:e24870. doi: 10.1002/pros.24870.
PubMed Abstract available

TILKI B, Hurmuz P, Yuce D, Ozyigit G, et al
Translation, Cross-Cultural Adaptation, and Psychometric Validation of the Turkish Version of the "Expanded Prostate Cancer Index Composite (EPIC)" in Prostate Cancer Patients.
Prostate. 2025 Feb 23:e24878. doi: 10.1002/pros.24878.
PubMed Abstract available

RETRACTION: Stat3 Enhances the Growth of LNCaP Human Prostate Cancer Cells in Intact and Castrated Male Nude Mice.
Prostate. 2025 Feb 21:e24872. doi: 10.1002/pros.24872.
PubMed

BRITTON CJ, Andrews JR, Arafa A, Kim Y, et al
Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single-Institution Pilot Study.
Prostate. 2025 Feb 20:e24861. doi: 10.1002/pros.24861.
PubMed Abstract available

HACIOGLU MB, Kucukarda A, Gokmen I, Gurbuz AF, et al
Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization.
Prostate. 2025 Feb 19. doi: 10.1002/pros.24876.
PubMed Abstract available

KAMBE T, Kubota M, Yamasaki T, Kawakita M, et al
Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy.
Prostate. 2025 Feb 19:e24875. doi: 10.1002/pros.24875.
PubMed Abstract available

HABAULT J, Franco JL, Ha S, Schneider JA, et al
In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
Prostate. 2025 Feb 16:e24868. doi: 10.1002/pros.24868.
PubMed Abstract available

KAVAK EE, Dilli I
Progression-Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer.
Prostate. 2025 Feb 13:e24871. doi: 10.1002/pros.24871.
PubMed Abstract available

DIAMAND R, Bernard PL, Mjaess G, Benijts J, et al
Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A two-year patient-reported and oncological assessment.
Prostate. 2025;85:115-122.
PubMed Abstract available

CHAI H, Miyasaka Y, Hagiwara Y, Souda H, et al
Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.
Prostate. 2025;85:123-129.
PubMed Abstract available

YANAI Y, Kosaka T, Mikami S, Arai M, et al
Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.
Prostate. 2025;85:308-314.
PubMed Abstract available

January 2025

NISHIMOTO M, De Velasco MA, Yamamoto Y, Fujimoto S, et al
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate.
Prostate. 2025 Jan 31:e24865. doi: 10.1002/pros.24865.
PubMed Abstract available

SUN Y, Zhu J, Zhong H, Zhang Z, et al
Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk.
Prostate. 2025 Jan 29:e24859. doi: 10.1002/pros.24859.
PubMed Abstract available

SHEN C, Chen Z, Hu FH, Wang W, et al
Reassessing the Role of Low PSA in Prognosis Across Grades of Prostate Cancer: A Cohort Study.
Prostate. 2025 Jan 29:e24860. doi: 10.1002/pros.24860.
PubMed Abstract available

BEATRICI E, De Carne F, Frego N, Moretto S, et al
Optimizing Prostate Cancer Diagnostic Work-Up Through Micro-Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses.
Prostate. 2025 Jan 28:e24862. doi: 10.1002/pros.24862.
PubMed Abstract available

CIRULLI GO, Stephens A, Chiarelli G, Finati M, et al
Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.
Prostate. 2025 Jan 27:e24856. doi: 10.1002/pros.24856.
PubMed Abstract available

BESIROGLU H, Kadihasanoglu M
The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostate. 2025 Jan 26:e24857. doi: 10.1002/pros.24857.
PubMed Abstract available

STANGL-KREMSER J, Ricaurte-Fajardo A, Huicochea Castellanos S, Martinez-Fundichely A, et al
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.
Prostate. 2025 Jan 23:e24853. doi: 10.1002/pros.24853.
PubMed Abstract available

UEDA T, Hayakawa K, Horiguchi G, Murashita J, et al
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer.
Prostate. 2025 Jan 15:e24855. doi: 10.1002/pros.24855.
PubMed Abstract available

BELKACEMI Y, Coraggio G, Debbi K, Sirmai L, et al
Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study.
Prostate. 2025 Jan 14:e24852. doi: 10.1002/pros.24852.
PubMed Abstract available

BAHRI RA, Mohammadi A, Yar EZ, Rezayat M, et al
Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis.
Prostate. 2025 Jan 12:e24851. doi: 10.1002/pros.24851.
PubMed Abstract available

KATO H, Goto Y, Kojima S, Onoda Y, et al
Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer.
Prostate. 2025 Jan 7:e24850. doi: 10.1002/pros.24850.
PubMed Abstract available

ANJALY K, Tiku AB
Exogenous Treatment of Caffeic Acid and Methylglyoxal Synergistically Enhances Anticancer Effect in Prostate Cancer via Inhibition of Glyoxalase-1.
Prostate. 2025 Jan 2. doi: 10.1002/pros.24849.
PubMed Abstract available

TANG CY, Li JJX, Leung KL, Ma HY, et al
Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.
Prostate. 2025;85:97-104.
PubMed Abstract available

December 2024

SUZUKI K, Hara T, Watanabe H, Nakane K, et al
Rapid and Deep Prostate-Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Multi-Intuitional Analysis.
Prostate. 2024 Dec 27. doi: 10.1002/pros.24847.
PubMed Abstract available

BARONE B, Amicuzi U, Massanova M, Napolitano L, et al
The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.
Prostate. 2024 Dec 23. doi: 10.1002/pros.24845.
PubMed Abstract available

ABER ER, Carducci MA, Paller CJ, Denmeade SR, et al
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.
Prostate. 2024 Dec 22. doi: 10.1002/pros.24841.
PubMed Abstract available

YORIOKA MAW, Murta CB, Leite KRM, Cardili L, et al
ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era.
Prostate. 2024 Dec 9:e24835. doi: 10.1002/pros.24835.
PubMed Abstract available

CHIARELLI G, Davis M, Stephens A, Finati M, et al
Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen.
Prostate. 2024 Dec 9:e24834. doi: 10.1002/pros.24834.
PubMed Abstract available

IWAHASHI Y, Wakamiya T, Kawabata H, Deguchi R, et al
Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.
Prostate. 2024 Dec 5. doi: 10.1002/pros.24831.
PubMed Abstract available

OLDAN JD, Rowe SP, Schroeder JA
Evaluation of online teaching modules for PSMA PET interpretation.
Prostate. 2024;84:1419-1426.
PubMed Abstract available

ONAL C, Elmali A, Erbay G, Demirhan B, et al
Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients.
Prostate. 2024 Dec 1. doi: 10.1002/pros.24833.
PubMed Abstract available

MIYAHIRA AK, Soule HR, Pienta KJ
CHARGE: The "Big Questions" in Prostate Cancer for 2024.
Prostate. 2024 Dec 1. doi: 10.1002/pros.24829.
PubMed

November 2024

MIYAHIRA AK, Sharifi M, Chesner LN, El-Kenawi A, et al
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2024 Nov 27. doi: 10.1002/pros.24826.
PubMed Abstract available

HE E, Li Y, Zhao R, Kong Q, et al
IL7 as a Risk Factor for Prostate Cancer: Implications for T Cell Apoptosis and Infiltration in the Tumor Microenvironment.
Prostate. 2024 Nov 26. doi: 10.1002/pros.24830.
PubMed Abstract available

GLADIS PUSHPARATHI VP, Justin Xavier D, Chitra P, Kannan G, et al
Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model.
Prostate. 2024 Nov 25:e24827. doi: 10.1002/pros.24827.
PubMed Abstract available

NAGASAKA H, Sato S, Suzuki A, Terao H, et al
Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer.
Prostate. 2024 Nov 20. doi: 10.1002/pros.24825.
PubMed Abstract available

RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
Prostate. 2024 Nov 17. doi: 10.1002/pros.24822.
PubMed

JUNIOR EP, Gomes EFDA, de Lima MFR, Raimundo JVS, et al
Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for Progression and Prognostic Assessment.
Prostate. 2024 Nov 13. doi: 10.1002/pros.24824.
PubMed Abstract available

BIALAS P, Kobayashi T, Hellsten R, Krzyzanowska A, et al
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.
Prostate. 2024 Nov 11. doi: 10.1002/pros.24820.
PubMed Abstract available

TAKAHASHI T, Nakashima M, Maruno K, Hazama T, et al
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System.
Prostate. 2024 Nov 10. doi: 10.1002/pros.24821.
PubMed Abstract available

TAO H, Wu F, Li R, Du X, et al
Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
Prostate. 2024 Nov 3. doi: 10.1002/pros.24817.
PubMed Abstract available

ZHAO X, Sakamoto S, Ishikawa H, Yamada Y, et al
Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.
Prostate. 2024 Nov 3. doi: 10.1002/pros.24818.
PubMed Abstract available

October 2024

WEI X, Zhao J, Nie L, Shi Y, et al
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients.
Prostate. 2024 Oct 28. doi: 10.1002/pros.24809.
PubMed Abstract available

FINATI M, Morrison C, Stephens A, Chiarelli G, et al
Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.
Prostate. 2024 Oct 28:e24803. doi: 10.1002/pros.24803.
PubMed Abstract available

WHYNE EZ, Jeon-Slaughter H, Kelly K, Dowell JE, et al
Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective Study.
Prostate. 2024 Oct 28. doi: 10.1002/pros.24811.
PubMed Abstract available

DI BELLO F, Jannello LMI, Baudo A, de Angelis M, et al
Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type.
Prostate. 2024 Oct 24:e24816. doi: 10.1002/pros.24816.
PubMed Abstract available

ERTL IE, Lemberger U, Rajwa P, Petrov P, et al
Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
Prostate. 2024 Oct 23. doi: 10.1002/pros.24815.
PubMed Abstract available

SHUKLA S, Osumi T, Al-Toubat M, Serrano S, et al
Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased alpha-Catenin.
Prostate. 2024 Oct 20. doi: 10.1002/pros.24812.
PubMed Abstract available

YANAGISAWA T, Fukuokaya W, Hatakeyama S, Narita S, et al
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813.
PubMed Abstract available

SEMWAL H, Ladbury C, Sabbagh A, Mohamad O, et al
Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.
Prostate. 2024 Oct 13. doi: 10.1002/pros.24793.
PubMed Abstract available

FALKENBACH F, Schmalhofer ML, Tian Z, Mazzucato G, et al
Size and SUV(max) define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.
Prostate. 2024 Oct 9. doi: 10.1002/pros.24806.
PubMed Abstract available

TSAI K, Xu P, Guo J, Dean N, et al
Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
Prostate. 2024;84:1344-1351.
PubMed Abstract available

September 2024

DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al
Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
Prostate. 2024 Sep 30. doi: 10.1002/pros.24799.
PubMed Abstract available

NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al
Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
Prostate. 2024 Sep 30. doi: 10.1002/pros.24802.
PubMed Abstract available

YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al
The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617.
Prostate. 2024 Sep 29. doi: 10.1002/pros.24804.
PubMed Abstract available

JIRASKO M, Vitak R, Pecen L, Pinkeova A, et al
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.
Prostate. 2024 Sep 27. doi: 10.1002/pros.24801.
PubMed Abstract available

MURTA CB, Junior JP, de Souza Filho PHF, de Godoy Junior PC, et al
Prostate cancer focal therapy: surgeon experience influences oncological results.
Prostate. 2024 Sep 26. doi: 10.1002/pros.24800.
PubMed Abstract available

TRAN EU, Ovruchesky E, Yamamoto K, Marley S, et al
Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
Prostate. 2024 Sep 22. doi: 10.1002/pros.24798.
PubMed Abstract available

TANAKA N, Izumi K, Nakai Y, Shima T, et al
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
Prostate. 2024 Sep 20. doi: 10.1002/pros.24796.
PubMed Abstract available

WONG CH, Ko IC, Leung DK, Siu B, et al
Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.
Prostate. 2024 Sep 19. doi: 10.1002/pros.24797.
PubMed Abstract available

DE JESUS GNC, Pereira V, Karak P, Shearier E, et al
A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
Prostate. 2024 Sep 18. doi: 10.1002/pros.24795.
PubMed Abstract available

UEKI H, Jimbo N, Terakawa T, Hara T, et al
Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.
Prostate. 2024 Sep 15. doi: 10.1002/pros.24791.
PubMed Abstract available

KATO T, Sugihara E, Hata Y, Kawakami K, et al
Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer.
Prostate. 2024 Sep 15. doi: 10.1002/pros.24792.
PubMed Abstract available

LIU X, Zhu J, Shi MQ, Pan YS, et al
Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography.
Prostate. 2024 Sep 12. doi: 10.1002/pros.24789.
PubMed Abstract available

BOIARSKY D, Tewari AK, Gulhan DC, Bakouny Z, et al
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
Prostate. 2024 Sep 9. doi: 10.1002/pros.24788.
PubMed Abstract available

MATRONE F, Del Ben F, Montico M, Muraro E, et al
Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy.
Prostate. 2024 Sep 6. doi: 10.1002/pros.24787.
PubMed Abstract available

HIMMELSBACH R, Hacklander A, Weishaar M, Morlock J, et al
Retrospective analysis of the learning curve in perineal robot-assisted prostate biopsy.
Prostate. 2024;84:1165-1172.
PubMed Abstract available

OZKAYA M, Simsekoglu MF, Kalender G, Sahin KC, et al
Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
Prostate. 2024;84:1146-1156.
PubMed Abstract available

BARRIERE H, Kaulanjan K, Stempfer G, Mollard P, et al
Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.
Prostate. 2024;84:1112-1118.
PubMed Abstract available

WEI Y, Wang H, Xie D, Lu J, et al
Analysis of three primary prostatic sarcoma cases and literature review.
Prostate. 2024;84:1218-1223.
PubMed Abstract available

CHEN VS, James C, Khemmani M, Desai S, et al
A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy.
Prostate. 2024;84:1251-1261.
PubMed Abstract available

ADAMS ES, Deivasigamani S, Kotamarti S, Wolf S, et al
Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes.
Prostate. 2024;84:1224-1233.
PubMed Abstract available

MADENDERE S, Kilic M, Zoroglu H, Sarikaya AF, et al
Natural history of histologically benign PIRADS 4-5 lesions in multiparametric MRI: Real-life experience in an academic center.
Prostate. 2024;84:1262-1267.
PubMed Abstract available

FALKENBACH F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, et al
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound.
Prostate. 2024 Sep 1. doi: 10.1002/pros.24785.
PubMed Abstract available

LU S, Lamba M, Wang J, Dong Z, et al
Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
Prostate. 2024 Sep 1. doi: 10.1002/pros.24786.
PubMed Abstract available

August 2024

TANEGASHIMA T, Shiota M, Eto M
Reply to Letter to the Editor on "Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients".
Prostate. 2024 Aug 21. doi: 10.1002/pros.24784.
PubMed

WANG J, Lao Y, Guan X, Li Z, et al
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
Prostate. 2024 Aug 21. doi: 10.1002/pros.24671.
PubMed

SAHEB SHARIF-ASKARI F, Al-Shahrabi R, Al Shareef Z
Response to the letter to the editor: Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
Prostate. 2024 Aug 21. doi: 10.1002/pros.24779.
PubMed

SWAMI U, Xie B, Young C, Ramaswamy K, et al
Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
Prostate. 2024 Aug 20. doi: 10.1002/pros.24777.
PubMed Abstract available

LI EV, Lee MS, Guo J, Dean N, et al
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate.
Prostate. 2024 Aug 18. doi: 10.1002/pros.24781.
PubMed Abstract available

HSIEH CL, Do AD, Hsueh CY, Raboshakga MO, et al
L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.
Prostate. 2024 Aug 18. doi: 10.1002/pros.24782.
PubMed Abstract available

LIU T, Joshu CE, Lu J, Prizment A, et al
Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study.
Prostate. 2024 Aug 15. doi: 10.1002/pros.24774.
PubMed Abstract available

WANG H, He K, Liu Y, Yang L, et al
Expression and immune infiltration studies of IL-33-ST2-NF-kappaB signaling pathway in prostate cancer.
Prostate. 2024 Aug 7. doi: 10.1002/pros.24778.
PubMed Abstract available

WAKAMORI C, De Velasco MA, Sakai K, Kura Y, et al
A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.
Prostate. 2024 Aug 7. doi: 10.1002/pros.24776.
PubMed Abstract available

ONAL C, Guler OC, Torun N, Elmali A, et al
Impact of definitive radiotherapy on metabolic response measured with (68)Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.
Prostate. 2024 Aug 6. doi: 10.1002/pros.24775.
PubMed Abstract available

GREENLAND NY, Cooperberg MR, Carroll PR, Cowan JE, et al
Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
Prostate. 2024;84:1076-1085.
PubMed Abstract available

PETERS DE, Brownlee M, Layne-Colon D, Slusher BS, et al
Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus).
Prostate. 2024;84:1086-1088.
PubMed Abstract available

July 2024

SCHMIT S, Malshy K, Ochsner A, Golijanin B, et al
Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing.
Prostate. 2024 Jul 25. doi: 10.1002/pros.24772.
PubMed Abstract available

FRIEDRICH NA, Gu L, Waller J, De Hoedt AM, et al
Real-world evidence of (18)F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
Prostate. 2024 Jul 19. doi: 10.1002/pros.24770.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2024 Jul 17. doi: 10.1002/pros.24768.
PubMed Abstract available

SUTERA P, Kim J, Kumar R, Deek RA, et al
PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
Prostate. 2024 Jul 17. doi: 10.1002/pros.24765.
PubMed Abstract available

TANEGASHIMA T, Shiota M, Tsukahara S, Mutaguch J, et al
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients.
Prostate. 2024 Jul 10. doi: 10.1002/pros.24769.
PubMed Abstract available

WENZEL M, Wagner N, Hoeh B, Siech C, et al
Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
Prostate. 2024 Jul 10. doi: 10.1002/pros.24767.
PubMed Abstract available

JASMINE S, Mandl A, Krueger TEG, Dalrymple SL, et al
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Prostate. 2024;84:909-921.
PubMed Abstract available

June 2024

KAYAR R, Tokuc E, Ozsoy E, Demir S, et al
The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI-RADS 3 lesions on multiparametric magnetic resonance imaging.
Prostate. 2024 Jun 26. doi: 10.1002/pros.24762.
PubMed Abstract available

MASSANOVA M, Barone B, Caputo VF, Napolitano L, et al
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study.
Prostate. 2024 Jun 25. doi: 10.1002/pros.24761.
PubMed Abstract available

PRAKASH P, Verma S, Gupta S
Influence of microbiome in intraprostatic inflammation and prostate cancer.
Prostate. 2024 Jun 20. doi: 10.1002/pros.24756.
PubMed Abstract available

MALSHY K, Ochsner A, Homer A, Allu S, et al
Consistent predictive ability of prostate-specific antigen density prediction model for clinically significant prostate cancer across age strata.
Prostate. 2024 Jun 20. doi: 10.1002/pros.24757.
PubMed Abstract available

CORDOBA SANCHEZ J, Monge-Escartin I, Gil J, Carrera C, et al
Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.
Prostate. 2024 Jun 18. doi: 10.1002/pros.24755.
PubMed Abstract available

ABRAMOVIC I, Pezelj I, Dumbovic L, Skara Abramovic L, et al
LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
Prostate. 2024 Jun 2. doi: 10.1002/pros.24749.
PubMed Abstract available

DONG Q, Wang C, Shen D, Ma Y, et al
Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
Prostate. 2024;84:780-787.
PubMed Abstract available

BUTTNER T, Gartner F, Essler M, Weiten R, et al
Key learnings from concordant systematic biopsies in prostate-specific membrane antigen positron emission tomography/computed tomography-guided prostate biopsies: Enhancing targeting accuracy.
Prostate. 2024;84:772-779.
PubMed Abstract available

FLETCHER SA, Mamawala MM, Holler AE, Bhanji Y, et al
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
Prostate. 2024;84:723-730.
PubMed Abstract available

BENNETT R 4TH, Li EV, Ho AY, Aguiar JA, et al
Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
Prostate. 2024;84:717-722.
PubMed Abstract available

CHECCUCCI E, De Cillis S, Alladio E, Piramide F, et al
Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy.
Prostate. 2024;84:832-841.
PubMed Abstract available

May 2024

WENZEL M, Hoeh B, Hurst F, Koll F, et al
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
Prostate. 2024 May 29. doi: 10.1002/pros.24754.
PubMed Abstract available

TOUMA N, Larose M, Ouellet J, Bedard-Tremblay D, et al
External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer patients.
Prostate. 2024 May 27. doi: 10.1002/pros.24742.
PubMed Abstract available

TIRUYE T, Roder D, FitzGerald LM, O'Callaghan M, et al
Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
Prostate. 2024 May 26. doi: 10.1002/pros.24750.
PubMed Abstract available

FERRO M, Crocetto F, La Civita E, Fiorenza M, et al
Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
Prostate. 2024 May 26. doi: 10.1002/pros.24752.
PubMed Abstract available

ABEDALI Z, Woloshuk A, Cary C, Boris RS, et al
Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer.
Prostate. 2024 May 16. doi: 10.1002/pros.24743.
PubMed Abstract available

BUTTNER T, Klumper N, Weiten R, Lossin P, et al
Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
Prostate. 2024 May 15. doi: 10.1002/pros.24747.
PubMed Abstract available

NAKAI Y, Tanaka N, Asakawa I, Ohnishi K, et al
Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
Prostate. 2024 May 12. doi: 10.1002/pros.24744.
PubMed Abstract available

MACKAY S, Oduor IO, Burch TC, Main BP, et al
Increased alpha2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer.
Prostate. 2024 May 12. doi: 10.1002/pros.24724.
PubMed Abstract available

ASHIDA S, Kawada C, Tanaka H, Kurabayashi A, et al
Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer.
Prostate. 2024 May 9. doi: 10.1002/pros.24723.
PubMed Abstract available

YIN J, Daryanani A, Lu F, Ku AT, et al
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
Prostate. 2024 May 6. doi: 10.1002/pros.24718.
PubMed Abstract available

HEETMAN JG, Paulino Pereira LJ, Kelder JC, Soeterik TFW, et al
The additional value of (68)Ga-PSMA PET/CT SUVmax in predicting ISUP GG >/= 2 and ISUP GG >/= 3 prostate cancer in biopsy.
Prostate. 2024 May 5. doi: 10.1002/pros.24716.
PubMed Abstract available

QAZI SU, Altaf Z, Zafar M, Tariq MA, et al
Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
Prostate. 2024;84:525-538.
PubMed Abstract available

ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al
Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.
Prostate. 2024;84:513-524.
PubMed Abstract available

BERG FM, Correia ETO, Abenojar EC, Basilion JP, et al
Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease.
Prostate. 2024;84:682-693.
PubMed Abstract available

SIMANEK V, Vrzakova R, Vitak R, Jirasko M, et al
Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
Prostate. 2024;84:656-665.
PubMed Abstract available

KOSTECKA LG, Mendez S, Li M, Khare P, et al
Cancer cells employ lipid droplets to survive toxic stress.
Prostate. 2024;84:644-655.
PubMed Abstract available

April 2024

KARSH L, Du S, He J, Waters D, et al
Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
PubMed Abstract available

MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
PubMed Abstract available

NGUYEN AM, Carter GC, Wilson LM, Canfield S, et al
Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score(R) (GPS(TM)) assay.
Prostate. 2024 Apr 26. doi: 10.1002/pros.24709.
PubMed Abstract available

CHARLTON PV, O'Reilly D, Philippou Y, Rao SR, et al
Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
Prostate. 2024 Apr 23. doi: 10.1002/pros.24715.
PubMed Abstract available

KAREGAR-NIAVOL R, Ghaffari F, Saravi A, Fotokian Z, et al
Translation and validation of a lifestyle questionnaire related to prostate cancer.
Prostate. 2024 Apr 21. doi: 10.1002/pros.24713.
PubMed Abstract available

MARSHALL CH, Gondek LP, Daniels V, Lu C, et al
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Prostate. 2024 Apr 20. doi: 10.1002/pros.24712.
PubMed Abstract available

JIA T, Liu C, Guo P, Xu Y, et al
FOXA1 regulates ribosomal RNA transcription in prostate cancer.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24714.
PubMed Abstract available

ZHAO F, Zhao J, Wei X, Shi Y, et al
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24710.
PubMed Abstract available

GRINDEDAL EM, Zucknick M, Stormorken A, Ronne E, et al
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24711.
PubMed Abstract available

CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al
An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
Prostate. 2024 Apr 12. doi: 10.1002/pros.24701.
PubMed Abstract available

BROWN LK, Kanagasabai T, Li G, Celada SI, et al
Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
Prostate. 2024 Apr 11. doi: 10.1002/pros.24706.
PubMed Abstract available

MARTELIN N, De Witt B, Chen B, Eschwege P, et al
Development and validation of an imageless machine-learning algorithm for the initial screening of prostate cancer.
Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
PubMed Abstract available

MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
PubMed Abstract available

ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy.
Prostate. 2024;84:491-501.
PubMed Abstract available

GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
PubMed Abstract available

KIM J, Park S, Kim S, Ryu S, et al
Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
PubMed Abstract available

KU HC, Cheng E, Cheng CF
A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
PubMed Abstract available

March 2024

SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al
Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
PubMed Abstract available

MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
PubMed Abstract available

DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al
CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
PubMed Abstract available

ONAL C, Guler OC, Erbay G, Elmali A, et al
The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
PubMed Abstract available

DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al
Other-cause mortality in incidental prostate cancer.
Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
PubMed Abstract available

HEERS H, Chwilka O, Huber J, Vogelmeier C, et al
VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
PubMed Abstract available

GU J, Chery L, Gonzalez GMN, Huff C, et al
A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.
Prostate. 2024 Mar 13. doi: 10.1002/pros.24686.
PubMed Abstract available

BRENNEN WN, Le Magnen C, Karkampouna S, Anselmino N, et al
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
Prostate. 2024 Mar 7. doi: 10.1002/pros.24682.
PubMed Abstract available

HUANG H, Liu Z, Ma Y, Shao Y, et al
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Prostate. 2024;84:376-388.
PubMed Abstract available

February 2024

KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
PubMed Abstract available

YE PC, Leu WJ, Yeh TY, Hsu YT, et al
A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Prostate. 2024 Feb 20. doi: 10.1002/pros.24678.
PubMed Abstract available

LUO LS, Huang J, Luan HH, Mubarik S, et al
Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990-2019: A comparable study of key nations with emerging economies.
Prostate. 2024 Feb 8. doi: 10.1002/pros.24673.
PubMed Abstract available

ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
Prostate. 2024 Feb 4. doi: 10.1002/pros.24674.
PubMed Abstract available

HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al
Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors.
Prostate. 2024 Feb 4. doi: 10.1002/pros.24672.
PubMed Abstract available

January 2024

PANACH-NAVARRETE J, Gonzalez-Marrachelli V, Morales-Tatay JM, Garcia-Morata F, et al
Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
Prostate. 2024 Jan 11. doi: 10.1002/pros.24670.
PubMed Abstract available

WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
PubMed Abstract available

DE KOUCHKOVSKY I, Chan E, Schloss C, Poehlein C, et al
Diagnosis and management of neuroendocrine prostate cancer.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24664.
PubMed Abstract available

ZHANG C, Tu X, Dai J, Zhang Z, et al
Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24669.
PubMed Abstract available

OZAWA Y, Nohara S, Nakamura K, Hattori S, et al
Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24668.
PubMed Abstract available

December 2023

MACKAY S, Oduor IO, Burch TC, Troyer DA, et al
Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma.
Prostate. 2023 Dec 27. doi: 10.1002/pros.24666.
PubMed Abstract available

PELLEGRINO F, Stabile A, Sorce G, Mazzone E, et al
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Prostate. 2023 Dec 27. doi: 10.1002/pros.24665.
PubMed Abstract available

XIE H, Chen J, Ma Z, Gao Y, et al
PrLZ regulates EMT and invasion in prostate cancer via the TGF-beta1/p-smad2/miR-200 family/ZEB1 axis.
Prostate. 2023 Dec 25. doi: 10.1002/pros.24647.
PubMed Abstract available

CANCEL M, Crottes D, Bellanger D, Bruyere F, et al
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
Prostate. 2023 Dec 19. doi: 10.1002/pros.24655.
PubMed Abstract available

D'AGOSTINO GR, Badalamenti M, Stefanini S, Baldaccini D, et al
Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
Prostate. 2023 Dec 19. doi: 10.1002/pros.24657.
PubMed Abstract available

LUKEZ A, Handorf E, Mendenhall NP, Henderson RH, et al
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
Prostate. 2023 Dec 18. doi: 10.1002/pros.24660.
PubMed Abstract available

MOON D, Hauck JS, Jiang X, Quang H, et al
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
Prostate. 2023 Dec 12. doi: 10.1002/pros.24654.
PubMed Abstract available

ZENG J, Zhang Y, Xu R, Chen H, et al
Nanomechanical-based classification of prostate tumor using atomic force microscopy.
Prostate. 2023;83:1591-1601.
PubMed Abstract available

BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al
Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
Prostate. 2023;83:1519-1528.
PubMed Abstract available

RAVI P, Kwak L, Devlies W, Xie W, et al
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Prostate. 2023 Dec 1. doi: 10.1002/pros.24653.
PubMed Abstract available

November 2023

AL SHAREEF Z, Al-Shahrabi R, Saheb Sharif-Askari F, AlDhmanie A, et al
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
Prostate. 2023 Nov 15:e24637. doi: 10.1002/pros.24637.
PubMed Abstract available

PALLER CJ, Barata PC, Lorentz J, Appleman LJ, et al
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate. 2023 Nov 14. doi: 10.1002/pros.24650.
PubMed Abstract available

MULLEN SA, Das D, Ziamiavaghi N, High R, et al
Association of plasma NRP2 and VEGF-C levels with prostate cancer disease severity.
Prostate. 2023 Nov 9. doi: 10.1002/pros.24648.
PubMed Abstract available

LI J, Wang K, Li S, Wu P, et al
Clinical study of multifactorial diagnosis in prostate biopsy.
Prostate. 2023;83:1494-1503.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640.
PubMed Abstract available

GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Prostate. 2023 Nov 1. doi: 10.1002/pros.24644.
PubMed Abstract available

October 2023

ALSAIDAN OA, Onobun E, Ye C, Lou L, et al
Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
Prostate. 2023 Oct 31. doi: 10.1002/pros.24645.
PubMed Abstract available

DI H, Wen Y
Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
PubMed Abstract available

FU W, Xu L, Chen Y, Zhang Z, et al
Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
Prostate. 2023 Oct 30. doi: 10.1002/pros.24642.
PubMed Abstract available

MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
Prostate. 2023 Oct 29. doi: 10.1002/pros.24643.
PubMed Abstract available

ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al
Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.
Prostate. 2023 Oct 27. doi: 10.1002/pros.24631.
PubMed Abstract available

HU HP, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, et al
Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Prostate. 2023 Oct 25. doi: 10.1002/pros.24638.
PubMed Abstract available

MITCHELL AP, Persaud S, Palyca P, Salner A, et al
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Prostate. 2023 Oct 16. doi: 10.1002/pros.24636.
PubMed Abstract available

SIEGELMANN-DANIELI N, Neiman V, Bareket-Samish A, Berger R, et al
Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Prostate. 2023 Oct 16. doi: 10.1002/pros.24622.
PubMed Abstract available

MENEZES RDS, Dornas MC, Campos CFF, Rodeiro DB, et al
Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
Prostate. 2023 Oct 15. doi: 10.1002/pros.24635.
PubMed Abstract available

PEDRAZA AM, Gupta R, Musheyev D, Pino T, et al
Microultrasound in the detection of the index lesion in prostate cancer.
Prostate. 2023 Oct 12. doi: 10.1002/pros.24628.
PubMed Abstract available

WANG L, Lyu C, Stadlbauer B, Buchner A, et al
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
Prostate. 2023 Oct 12. doi: 10.1002/pros.24632.
PubMed Abstract available

HOANG T, Sutera P, Nguyen T, Chang J, et al
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Prostate. 2023 Oct 9. doi: 10.1002/pros.24629.
PubMed Abstract available

LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Prostate. 2023 Oct 5. doi: 10.1002/pros.24630.
PubMed Abstract available

September 2023

ARAFA MA, Farhat KH, Khan FK, Rabah DM, et al
Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
Prostate. 2023 Sep 27. doi: 10.1002/pros.24625.
PubMed Abstract available

RAJWA P, Heidenreich J, Drzezga A, Schmidt M, et al
The diagnostic accuracy of (68) Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24627.
PubMed Abstract available

ZOU P, Chen Z, He Q, Zhuo Y, et al
Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24626.
PubMed Abstract available

KOELKER M, Labban M, Frego N, Ye J, et al
Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer.
Prostate. 2023 Sep 14. doi: 10.1002/pros.24624.
PubMed Abstract available

ULERI A, Baboudjian M, Tedde A, Rajwa P, et al
The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis.
Prostate. 2023 Sep 14. doi: 10.1002/pros.24623.
PubMed Abstract available

YAMADA Y, Sakamoto S, Sato K, Saito S, et al
Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
Prostate. 2023 Sep 10. doi: 10.1002/pros.24619.
PubMed Abstract available

ESEN B, Seymen H, Gurses B, Armutlu A, et al
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
Prostate. 2023 Sep 3. doi: 10.1002/pros.24621.
PubMed Abstract available

FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al
Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
Prostate. 2023 Sep 3. doi: 10.1002/pros.24620.
PubMed Abstract available

FRANCOLINI G, Banini M, Di Cataldo V, Detti B, et al
PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
Prostate. 2023;83:1201-1206.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.